Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Enhancing Patient-level RWD with AI/ML

Enhancing Patient-level RWD with AI/ML

  • August 16, 2021
  • Posted in AI

This post was last updated on October 15, 2021 at 1:23 pm

In a recent webinar with Datavant titled How AI/ML Enhance RWD For Precision Medicine, Prognos Health co-founder and Chief Medical Information Officer, Jason Bhan, MD and Chief Data Scientist, Adam Petranovich outlined how artificial intelligence (AI) and machine learning (ML) technologies are being used to add value to patient-level real-world data (RWD).

The duo set the stage by discussing the overall strengths of AI/ML as well as some of the remaining challenges associated with the technology. According to Petranovich, AI/ML tools are best suited for automating simple tasks at scale and in a fraction of the time it would take a human. Examples include email filters and classifications, text processing, document discovery, image processing, anomaly detection, and pattern recognition. 

While these strengths are well documented, some key challenges including legislation limiting data rights and access, improper expectations surrounding the technology, and a shortage of data scientists continue to hinder the pace at which these tools are successfully leveraged. That being said, Petranovich firmly believes we are in a better position to capitalize on the capabilities of AI and ML today than ever before — thanks in large part to the increased availability of data, the commoditization of computing power and storage, and the consistent deployment of data modeling and frameworks. 

Strengths of AI/ML in RWD

When looked at under the RWD lens, the strengths of AI/ML become more concrete. For example, the automation capabilities of AI/ML are ideal for the preparation, enrichment, and standardization of RWD. The technology can help standardize units of measure for lab tests, automatically extract ICD, CPT and NDC codes, streamline LOINC tagging, and interpret free text fields in pathology and molecular diagnostic lab tests. 

From an anomaly detection perspective, AI/ML can be leveraged to flag potential clinical errors or data entry errors in patient-level RWD and detect and correct machine and lab biases. The technology can also be used to prioritize the datasets or features that add the most value to a model or process and expand patient cohorts for different clinical or commercial use cases.

How Prognos uses AI/ML

Prognos Health leverages AI and ML in a variety of ways to ensure the health data on its platform provides more value to customers. 

NLP for clinical data — Prognos uses natural language processing (NLP) to abstract information and hierarchies from large clinical texts. This technology is heavily tested on lab data to detect organs, conditions, procedures, anatomical sites, and more. It is also used to automatically link clinical concepts to diagnostic codes and determine whether a patient tested positive, negative, or inconclusive for a condition (e.g. melanoma) or molecular entity (e.g. PD-L1).  

Clinical data enrichment — Prognos applies machine learning algorithms to its lab data to fill in missing provider information (such as NPI), identify test value outliers for validation, and tag lab tests for hundreds of millions of records. This process helps ensure data accuracy and eliminates the need for clients to track down or verify this information themselves.

Patient utilization prediction — Prognos has also created a machine-learning algorithm that applies to its repository of laboratory, prescription, and claims information that predicts the future 12-month medical costs for a group of prospective health insurance members. This tool can help health plans quickly generate underwriting risk scores and quotes that are significantly more accurate than the industry standard.

Advanced patient insights — Using AI/ML, Prognos can predict and prioritize — with confidence — de-identified patients that will start or change therapies. This insight allows life science customers to use resources more efficiently, differentiate tactics, and prioritize PCPs to target with messaging. It also can help life science organizations identify and reach patients sooner, improving quality of life and reducing the likelihood of adverse events that could lead to hospitalization or death.
See first hand how these AI/ML investments enrich patient-level health data, leading to faster actionable insights for your life science or payer organization. Request a
customized demo with one of our clinical experts or data scientists today.

« Understanding disease phenotype is crucial in the fight against asthma
5 Benefits of Healthcare Data Marketplaces for Patient-Level RWD »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.